Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report

Guoliang Pi, Hanping He, Jianping Bi, Ying Li, Yanping Li, Yong Zhang, Mingwei Wang, Guang Han, Chi Lin

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

Introduction: Currently, the options are limited for the treatment of patients who have failed 2 lines of chemotherapy for advanced lung squamous cell carcinoma (SCC). Recently, nivolumab, a fully human IgG4 programmed death 1 immune checkpoint inhibitor antibody, was approved to treat patients with advanced stage, relapsed/refractory lung SCC. Although nivolumab has demonstrated antitumor activity with survival benefit in Caucasian patients, its efficacy in Asian patients is unknown. CaseReport: In this report, we describe a Chinese patient with relapsed advanced stage lung SCC who had an excellent response to nivolumab after only 2 doses without any adverse effects. Immunohistochemical analysis indicated the tumor was stained positive for programmed death-ligand 1. Conclusion: To our knowledge, this is the first report of satisfactory efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung SCC. Further clinical trials in Asian countries are needed to test whether nivolumab immunotherapy is a safe and effective treatment for Asian patients with lung SCC.

Original languageEnglish (US)
Article numbere5077
JournalMedicine (United States)
Volume95
Issue number40
DOIs
StatePublished - Jan 1 2016

    Fingerprint

Keywords

  • Lung squamous cell carcinoma
  • Nivolumab
  • PD-L1
  • Relapsed
  • Short-term

ASJC Scopus subject areas

  • Medicine(all)

Cite this